» Articles » PMID: 17363312

PLU-1 is an H3K4 Demethylase Involved in Transcriptional Repression and Breast Cancer Cell Proliferation

Overview
Journal Mol Cell
Publisher Cell Press
Specialty Cell Biology
Date 2007 Mar 17
PMID 17363312
Citations 241
Authors
Affiliations
Soon will be listed here.
Abstract

Posttranslational modification of chromatin by histone methylation has wide-ranging effects on nuclear function, including transcriptional regulation, maintenance of genome integrity, and epigenetic inheritance. The enzymes utilized to place histone methylation marks are well characterized, but the identity of a histone demethylation system remained elusive until recently. The discovery of histone demethylase enzymes capable of directly removing methyl groups from modified lysine residues has demonstrated that histone methylation is a dynamic modification. The most extensive family of histone demethylase enzymes identified so far contains a JmjC domain and catalyzes demethylation through a hydroxylation reaction. Here, we identify PLU-1, a transcriptional repressor implicated in breast cancer, as a histone demethylase enzyme that has the ability to reverse the trimethyl H3K4 modification state. Furthermore, we reveal that PLU-1-mediated H3K4 demethylase activity plays an important role in the proliferative capacity of breast cancer cells through repression of tumor suppressor genes, including BRCA1.

Citing Articles

Current advances and future directions in targeting histone demethylases for cancer therapy.

Shin J, Yoo H, Roe J Mol Cells. 2025; 48(3):100192.

PMID: 39938867 PMC: 11889978. DOI: 10.1016/j.mocell.2025.100192.


Cell signaling and transcriptional regulation of osteoblast lineage commitment, differentiation, bone formation, and homeostasis.

Zhu S, Chen W, Masson A, Li Y Cell Discov. 2024; 10(1):71.

PMID: 38956429 PMC: 11219878. DOI: 10.1038/s41421-024-00689-6.


Tumour cell-derived serglycin promotes IL-8 secretion of CAFs in gastric cancer.

Li X, Xie G, Chen J, Wang Y, Zhai J, Shen L Br J Cancer. 2024; 131(2):271-282.

PMID: 38862740 PMC: 11263384. DOI: 10.1038/s41416-024-02735-2.


KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges.

Li C, Wang W, Leung C, Yang G, Chen J Mol Cancer. 2024; 23(1):109.

PMID: 38769556 PMC: 11103982. DOI: 10.1186/s12943-024-02011-0.


Pharmacological potential of micheliolide: A focus on anti-inflammatory and anticancer activities.

Uddin J, Fatima M, Riaz A, Kamal G, Bin Muhsinah A, Ahmed A Heliyon. 2024; 10(6):e27299.

PMID: 38496875 PMC: 10944196. DOI: 10.1016/j.heliyon.2024.e27299.